The life science company Acucort has entered into a binding agreement with Glenmark Pharmaceuticals for the marketing and distribution of Zeqmelit in six European countries. The agreement covers the countries Germany, the Netherlands, the Czech Republic, Austria, Slovakia, and Ukraine. Glenmark will be responsible for the commercialization of the product in each respective market. - That we now have a binding commercial agreement in place with Glenmark is a very important milestone for AcuCort. Germany is one of Europe’s largest and most significant pharmaceutical markets, and the agreement confirms both the commercial potential of the product and our long-term expansion efforts, says Acucort’s CEO Jonas Jönmark.Glenmark bears responsibility for the marketing authorization for the product in the relevant markets and expects that the application will be submitted in the second half of this year.Zeqmelit has previously been launched in Sweden, Finland, Norway, and Denmark.